BD Unveils Groundbreaking Bioscience Innovations at the 5th China International Import Expo

Nov 07, 2022 18:24 CST Updated 18:24

BD

Medical Device R&D Manufacturer, Distributor

Shanghai, November 6, 2022 —— As BD participated in the China International Import Expo for the third consecutive year with a refreshed brand image commemorating its 125th anniversary, a series of internationally leading biotechnological innovations and solutions, including "Flow Cytometry Mapping" and single-cell multi-omics, were unveiled. These advancements will significantly enhance research capabilities in fundamental areas such as immunology, cell biology, and genomics, further unlocking potential therapeutic approaches in broader fields like virology, oncology, and cell therapy, thereby accelerating the entire value chain from innovation to productivity in the biopharmaceutical industry.

Mr. Chengzhi Hui (Associate Director of Research Market, Biosciences Division, Greater China, BD Medical), Mr. Tong Wang (Vice President, Biosciences Division, Greater China, BD Medical), Professor Bing Su (Director of Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine), Mr. Jianmin Deng (Senior Vice President, Global, and General Manager, Greater China, BD Medical), Mr. Rong Ji (National Equipment Sales Associate Director, Biosciences Division, Greater China, BD Medical)

Wang Tong, Vice President of BD Medical Greater China's Biosciences Division, stated: "We are highly honored to participate in the CIIE for the third consecutive year and, through this international platform, continuously bring our innovative research achievements in areas such as flow cytometry and single-cell multi-omics to China. We actively provide leading, efficient, and user-friendly solutions for Chinese researchers and clinical medical staff. This year, BD Medical Biosciences has introduced CellView."^TMBD FACSDiscover Imaging Technology^TMS8 Cell Sorter, BD Horizon RealYellow^TMAnd RealBlue^TMAI Fluorescent Dye Series, BD Rhapsody^TMSingle-cell multi-omics research platforms and other products. These innovations represent the global technical standards and future development trends in niche fields. We look forward to collaborating closely with China's scientific and clinical medical communities, applying innovative technologies to achieve groundbreaking discoveries, and contributing to the advancement of Healthy China."

Driven by Innovation as the Primary Force, Flow Cytometry Has Advanced Multidisciplinary Development Over the Past Fifty Years

Flow cytometry refers to the multi-parameter, rapid quantitative analysis of individual cells or other biological particles at the cellular and molecular level. This technology can analyze tens of thousands of cells at high speed and simultaneously measure multiple parameters from a single cell. With the advantages of high speed, precision, and accuracy, it is one of the most advanced cell quantitative analysis technologies today. BD is an innovator and leader in the global flow cytometry field, having launched the world's first commercial flow cytometer, FACS I, in 1973. This year marks the 50th anniversary of the global application of flow cytometry. Over the past 50 years, BD has continuously driven innovation as its primary motivation, leading every disruptive revolution in flow cytometry. Experts and clinical workers such as Director Bing Su of the Shanghai Institute of Immunology participated in the celebration of the 50th anniversary of the global application of flow cytometry.

In China, since the introduction of the first flow cytometer FACS III in 1981 by the Biology Department of Beijing Normal University, the application of flow cytometry in China has exceeded 40 years. Over the past four decades, flow cytometry has been widely used in multiple fields in China, including immunology, molecular biology, bacteriology, virology, cancer biology, and infectious disease surveillance. It has supported numerous globally remarkable scientific innovations, such as the first Chinese SARS-CoV-2 neutralizing antibody combination therapy.

At this CIIE, BD Medical preheated and promoted the launch of CellView.^TMImaging Technology's BD FACSDiscover^TMS8 Cell Sorter. This is the world's first full-spectrum flow cytometry cell sorter with image analysis capabilities. Its emergence marks the comprehensive entry of global flow cytometry from traditional and spectral flow stages into the new era of "Image·Spectrum" flow technology.

Based on spectral flow cytometry, BD FACSDiscover^TMS8 Cell Sorter through CellView^TMImaging Technology Integrates Real-Time Spatial and Morphological Information

CellView^TMThe innovation in imaging technology enables researchers to conduct high-parameter experiments and rapidly sort cells of interest with specific visual characteristics. This allows them to actually see the cells being analyzed and gain detailed insights into their internal operations. It opens an unprecedented door to cell research, enabling investigations to reach depths previously unattainable and answer questions that were once unimaginable. CellView^TMImaging technology, due to the tremendous transformation it has brought, graced the cover of the January issue of *Science* magazine this year.

From Innovation to Productivity: Providing One-Stop Solutions for Every Link in the Industrial Chain

Focusing on the practical application scenarios and needs of industry, academia, research, and medicine, BD is providing integrated solutions with stable standards for every link in the industry chain. During this year's CIIE, BD showcased a series of supporting products for flow cytometry and single-cell multi-omics, which will create a complete one-stop solution for China, ranging from high-dimensional and in-depth scientific research to GMP production and clinical applications.

This time, BD Medical has newly launched the BD Horizon RealYellow equipped on flow cytometers.^TM586, an innovative laser-specific fluorescent dye. This dye, optimized by AI, offers a series of advantages such as reduced spillover, brighter expression, versatile functionality, and stable performance. It can be used to replace PE on traditional flow cytometers, allowing for flexible adjustments in protocol design; it can also be used alongside PE on spectral flow cytometers to expand high-parameter research. The launch of this new product further enhances the BD Horizon RealYellow portfolio.^TMAnd RealBlue^TMThe series of fluorescent dyes facilitates flexible protocol design on both conventional and spectral flow cytometers, expanding high-parameter research.

In addition, BD also showcased the BD Rhapsody VDJ, currently the world's only platform that can simultaneously obtain transcriptome, proteome, immune repertoire, and mixed-sample research in a single experiment. Its research results can be integrated with flow cytometry analysis results at the protein level in immunology to jointly interpret biological questions, which is of great significance to researchers. The BD Rhapsody VDJ full-length analysis kit fills many previous gaps in terms of analyzable cell types, gene region coverage, and analytical precision. As a true single-cell multi-omics solution, it not only saves time and cost but also eliminates concerns about inter-batch data variability between different experimental runs, making it an urgently needed multi-omics solution for researchers.

Deng Jianmin, Global Senior Vice President of BD and General Manager of Greater China, stated: "Through the platform of the CIIE, BD continuously brings globally leading innovative products to China. In the field of bioscience, we launched the BD FACSLyric in 2020.^TMPaired with Duet^TMAn integrated solution for automatic preparation and automatic loading, Rhapsody was introduced in 2021.^TMSingle-cell multi-omics platform, this year introduced the epoch-making BD FACSDiscover^TMThe S8 Cell Sorter is a microcosm of BD's '125 years of unwavering innovation.' Starting from the CIIE, these innovations have gradually transitioned from exhibits to products, playing a crucial role in the entire industry chain of research, clinical applications, and GMP production. We are deeply proud of this. In the future, BD will continue to work closely with China's scientific researchers and clinicians to jointly build a healthier tomorrow."

Highlights Review: